

September 19, 2023


The power of multisector partnerships in vaccine manufacturing

Harnessing momentum toward vaccine equity and pandemic preparedness

Jessica Milman, MPH
Global Head, Center for Vaccine Innovation and Access
Acting Chief of Essential Medicines



Our work happens through established, trusted relationships across sectors



Partner continuity builds on success

Trust, knowhow, and deep mutual understanding enables innovation, efficiency, and impact.

Example

Serum Institute of India, PATH, and others have advanced the development of affordable and accessible vaccines for over two decades, including conjugate vaccines.




MenAfriVac® meningococcal meningitis A vaccine



Pneumosil® 10-valent pneumococcal vaccine



MenFive® pentavalent meningococcal meningitis vaccine



Diverse networks broaden potential

Visibility into potential collaborations and innovations not otherwise apparent—in and outside of pandemics.

Example

International, multisector relationships stemming from the 2009 influenza A/H1N1 pandemic were springboard for merging traditional egg-based vaccine production technology with cutting-edge science for COVID-19 vaccine development.




Technical assistance tips the balance toward progress

Transition past specific hurdles and on to the next milestone.

Example

- PATH provides tailored technical assistance across the entire vaccine development spectrum.
- In China, we provided support as Inovax readied its bivalent HPV vaccine, Cecolin, for WHO prequalification.



Thank you!

For more
information contact:

Jessica Milman

jmilman@path.org



